# Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

> **NCT05397405** · NA · RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 180 (estimated)

## Conditions studied

- Intracranial Artery Stenosis

## Interventions

- **DRUG:** PCSK9 inhibitor

## Key facts

- **NCT ID:** NCT05397405
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-23
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397405, "Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05397405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*